HomeScreenerUTHRProfile
F
35/100

United Therapeutics

UTHRPulmonary
📋
Analyst Summary
✓ VERIFIED2026-04-11

United Therapeutics (UTHR) is the lead sponsor of 9 active clinical trials listed on ClinicalTrials.gov[5], including 3 Phase 3[1], 2 Phase 2[2], 2 Phase 1[3], 1 Phase 4[4].

Trial NCT05943535[6] evaluates Placebo in Progressive Pulmonary Fibrosis with a target enrollment of 698 participants. Trial NCT03683186[7] evaluates Ralinepag in PAH with a target enrollment of 1000 participants. Trial NCT04905693[8] evaluates Inhaled Treprostinil in Idiopathic Pulmonary Fibrosis with a target enrollment of 1850 participants.

UTHR has 37 Form 4 insider filings recorded at the SEC in the past 30 days[9].

Sources

  1. ClinicalTrials.gov (2026-04-11)
  2. ClinicalTrials.gov (2026-04-11)
  3. ClinicalTrials.gov (2026-04-11)
  4. ClinicalTrials.gov (2026-04-11)
  5. ClinicalTrials.gov (2026-04-11)
  6. ClinicalTrials.gov · NCT05943535 (2026-03-31)
  7. ClinicalTrials.gov · NCT03683186 (2026-02-20)
  8. ClinicalTrials.gov · NCT04905693 (2026-03-31)
  9. SEC EDGAR · 0001082554 (2026-04-11)
🔬
Clinical Trials
9
NCT03045029Pulmonary Arterial Hypertension
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT03683186PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension, Connective Tissue Diseases, Familial Primary Pulmonary Hypertension, Vascular Diseases, Cardiovascular Diseases, Hypertension, Pulmonary, Lung Diseases, Respiratory Tract Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT04905693Idiopathic Pulmonary Fibrosis, Interstitial Lung Disease, Progressive Pulmonary Fibrosis
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05203510Pulmonary Arterial Hypertension
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05776225Interstitial Lung Disease, Pulmonary Hypertension
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT05943535Progressive Pulmonary Fibrosis, Interstitial Lung Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06388421Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Pulmonary Hypertension, Interstitial Lung Disease
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT06878560ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
NCT07224763ESRD (End-Stage Renal Disease), Kidney Transplantation, Xenotransplantation
Source ↗
clinicaltrials_gov · Retrieved 2026-04-11
👤
Insider Activity
1
37 filings
Source ↗
sec_edgar · Retrieved 2026-04-11
Not financial advice. BiotechSigns profiles are AI-generated from verified public sources (ClinicalTrials.gov, SEC EDGAR) and are for informational purposes only. Always do your own due diligence before making investment decisions.
Score Breakdown
Score Trend
2026-04-132026-06-02
Signal Summary
PDUFA Dates0
Insider Filings1
Clinical Trials1
Sector Peers (Pulmonary)
LQDALiquidia Technologies
D
Data Provenance
cik1 verified
clinical trial9 verified
insider buy1 verified
trial count5 verified
Every claim backed by source URL from ClinicalTrials.gov or SEC EDGAR